- NON-FINANCIAL REPORT
- JOIN US
- CONTACT US
-
NEURAXPHARM GROUP
See Neuraxpharm’s sites
Product | Indication | Dosage form | Strength |
---|---|---|---|
Ondansetron | Nausea & vomiting | Orodispersable tablets | 4 and 8 mg |
Otilonium bromide | Irritable bowel syndrome | Film-coated tablets | 40 mg |
Paracetamol / Tramadol | Analgesic | Effervescent tablets | 325/37.5 mg |
Prasugrel Base | Prophylaxis and therapy of thrombosis | Film-coated tablets | 5 and 10 mg |
Rivaroxaban | Thrombosis, stroke | Film-coated tablets | 10, 15 and 20 mg |
Rizatriptan | Migraine | Orodispersable tablets | 5 and 10 mg |
Solifenacin | Overactive bladder, urinary incontinence | Film-coated tablets | 5 and 10 mg |
Telmisartan | Hypertension | Tablets | 20, 40 and 80 mg |
Valsartan | Hypertension | Film-coated tablets | 40, 80, 160 and 320 mg |
Zolmitriptan | Migraine | Orodispersable tablets | 2.5 and 5 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.